On the September 29, 2021, Pudong New Area held commendation event for "2021 Outstanding Economic Contribution Enterprises ". ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. won the Price of Top 20 of "2020 Pudong New Area Innovation and Entrepreneurship Award ".

On September 28, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") wholly-owned subsidiary-ImmuneOnco BioPharm (Shanghai) Co., Ltd. was established in Zhangjiang Science City (hereinafter referred to as "ImmuneOnco BioPharm").

August 25, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. ( hereinafter referred to as "ImmuneOnco") announced that 3 phase Ib/IIa trials of company’s lead drug candidate, IMM01, Fc fusion protein targeting CD47，the first in China, combined with Azacytitin for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with Rituximab for relapsed/refractory B-cell lymphoma and with Inetetamab (CipterbinTM) in her2-positive solid tumors have been approved by the National Drug Products Administration (NMPA).

August 21, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the U.S. Food and Drug Administration (FDA) has granted permission to IMM2902, a bi-specific antibody-receptor recombinant protein targeting Human CD47xHER2 for HER2-expressing advanced solid tumors for the Investigational New Drug (IND) application in the United States.

August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been successfully finished.